TRAF4
Aliases:
This biomarker is also known as:- tumor necrosis receptor-associated factor 4A
- cysteine-rich domain associated with ring and TRAF domain
- cysteine-rich domain associated with RING and Traf domains protein 1
- MLN62
- TNF receptor-associated factor 4
- metastatic lymph node gene 62 protein
- TRAF4
- RNF83
- Cysteine-rich domain associated with RING and Traf domains protein 1
- Metastatic lymph node gene 62 protein
- CART1
- RING finger protein 83
- malignant 62
- MLN 62
Description…
TRAF4 is a member of the TNF receptor associated factor (TRAF) family. Members of the TRAF family are the major signal transducers for the TNF receptor (TNFR) superfamily and the interleukin-1 receptor/Toll-like receptor superfamily. TRAF4 is involved in the activation of NF-kappa-B and JNK, and in the regulation of cell survival and apoptosis.
Datasets
There are no datasets associated with this biomarker.
Attributes
| QA State: | Curated |
|---|---|
| Type: | Protein |
| HGNC Name: | TRAF4 |
The following organs have data associated with this biomarker…
Attributes
| Phase: | 2 |
|---|---|
| QA State: | Under Review |
Organ-specific information for this biomarker is currently being annotated or is "under review".
Logging in may give you privileges to view additional information.
Contact the
Informatics Center
if you believe you should have access to this biomarker.
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
- Multianalyte tests for the early detection of cancer: speedbumps and barriers.
- Use of a single-chain antibody library for ovarian cancer biomarker discovery.
- Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling.
- Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.